Wednesday, August 04, 2021 9:16:25 AM
Published: Aug. 3, 2021 at 4:51 p.m. ET
BETHESDA, Md., Aug 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain"), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 - 10.
BTIG Virtual Biotechnology Conference
Date: Monday, August 9TH
Time: 11:30 to 11:55 a.m. ET
Presenter: Eric Richman, Chief Executive Officer
Please contact your BTIG representative to listen to the live event and schedule a virtual one-on-one meeting with Gain's management team during the conference.
About BTIG Virtual Biotechnology Conference
The annual August conference will be held virtually. BTIG expects to host more than 120 corporate management teams throughout the two-day, private event which includes thematic panels featuring key opinion leaders, fireside chats, and one-on-one meetings.
For further information, please visit: www.BTIG.com
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx(TM) target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
For more information, visit https://www.gaintherapeutics.com/
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval or filing, may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on May 5 2021, as well as other documents that may be filed by the Company from time to time.
New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this earnings release to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this earnings release.
Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 617-430-7576
daniel@lifesciadvisors.com
Recent GANX News
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 04/24/2024 01:25:00 PM
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer • GlobeNewswire Inc. • 04/08/2024 01:25:00 PM
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/01/2024 01:25:00 PM
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Gain Therapeutics to Present at Public Ventures Discovery Day • GlobeNewswire Inc. • 03/15/2024 06:30:11 PM
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 02/27/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:17 PM
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight • GlobeNewswire Inc. • 02/14/2024 05:29:34 PM
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 02:56:04 PM
- Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:26:33 PM
- Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2024 09:09:27 PM
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024 • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/02/2024 05:15:12 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:03 PM
- Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model • GlobeNewswire Inc. • 12/01/2023 01:00:00 PM
- Gain Therapeutics to Participate in AI Driven Drug Discovery Summit • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option • GlobeNewswire Inc. • 11/24/2023 06:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/24/2023 11:07:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 10:27:26 PM
- Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants • GlobeNewswire Inc. • 11/21/2023 01:54:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/20/2023 09:22:52 PM
- Gain Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 11/20/2023 09:03:43 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM